Skip to main content
  • Notice of Privacy Incident
  • Medicaid Provider Termination Alert: Revalidation deadlines are approaching. Failure by providers to revalidate will lead to termination and payment suspension. Check your account now at https://impact.illinois.gov/ to learn if your required revalidation is due this month. More revalidation information here.
Elizabeth M. Whitehorn, Director

Drugs and Therapeutics (D & T) Committee Drugs Under Review for: March 20, 2013

Drug Name Review Type Class Manufacturer
Quillivant XR New Drug Initial Review Stimulants/ADHD Pfizer
Xeljanz New Drug Initial Review Rheumatoid Arthritis Pfizer
Aubagio New Drug Initial Review Multiple Sclerosis Genzyme
Eliquis New Drug Initial Review Oral Anticoagulant Bristol Myers-Squibb
Sklice New Drug Initial Review Pediculicide Sanofi Pasteur
Gattex New Drug Initial Review GLP-2 NPS Pharmaceuticals
Oxtellar XR New Drug Initial Review Anticonvulsant Supernus Pharmaceuticals
Tudorza Pressair New Drug Initial Review Long-acting Anticholingeric Forest
Natroba New Drug Appeal Pediculicide ParaPRO
Brilinta PDL Appeal Platelet Aggregation Inhibitor AstraZeneca
Latuda PDL Appeal Atypical Antipsychotic Sunovion